Jaimie's primary responsibilities are to coordinate calendars, events, and company meetings for RA Venture Partners and EIRs. in Business Administration in Management with a Minor in Biology from UMass Amherst Commonwealth Honors College. His primary responsibilities are to advise RA Capital on private investments, coordinate with portfolio companies regarding deal structures and terms, and counsel RA Ventures on new company formation. By Matt Grobar. Rez Halse is President of RAVen, also known as RA Ventures, RA Capitals company creation incubator. His graduate research investigated the role of fimbria in Bordetella adherence and virulence. Prior to her Managing Director role at NVF, Nandita held various positions at Novartis in Business Development and Licensing and as a key member of the Kymriah Global Program Team, helping to bring this novel cell therapy to market. Pieter holds a BA from Trinity College and a JD from Yale Law School. He holds a Bachelors degree in Electronics and Communications from Anna University, and a Masters degree in Computer Science from Northeastern University. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Daniel has a BS in Mechanical Engineering from Lehigh University and a MS in Energy Policy & Climate from Johns Hopkins University. Previously, Zach covered the neurology, ophthalmology, and dermatology landscapes. Derek DiRocco is a Partner at RA Capital Management. Merediths primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. During his time at Flagship, Tom also served as Co-Founder, Head of Translational Biology at a stealth ProtoCo. Jesse also held research leadership roles at Moderna Therapeutics and Millennium Pharmaceuticals, where he was responsible for developing novel platforms and leading discovery programs. Prior to joining RA, Brigid was the Head of Venture Investments for BHP Ventures, the internal venture capital unit within the worlds largest mining company, where her investment mandate was to help the decarbonization of BHPs operations and to improve the sustainability of resource extraction. He worked previously as an Associate Managing Editor at EBSCO Health, and as a Medical Writer at IC Axon and Publicis Life Brands International. Garrett Heffner is an EIR at RA Ventures, focusing on genetic medicines. He worked previously as the Director of Business Systems at Bain Capital Credit, and as a Senior Systems Analyst at eSecLending, LLC. Prior to RA, Fuad was a Flagship Labs Fellow at Flagship Pioneering. Brett Scheller is a Compliance Officer at RA Capital Management. Vikram trained in clinical pathology at the Brigham and Womens Hospital where he was chief resident. Michael Gillespie is an Analyst on the Venture Team at RA Capital Management. Prior to this role, Kate worked with the Venture team evaluating early stage investment opportunities and mapped a number of competitive landscapes, including ophthalmology, lower GI, and non-viral liver disease. Christy has an MS in Immunology from National Taiwan University, a PhD in Immunology and Microbial Pathogenesis from Cornell University, and a mini-MBA in BioPharma Innovation from Rutgers Business School. Soumya has contributed to over 75 drug discovery programs ranging from small startups to large pharma, leading to nine development candidates currently in various stages of clinical trials. Anurag holds a BSE in Biomedical Engineering and a BS in Economics from Duke University. His responsibilities include managing the portfolios public equity positions, monitoring market, sector, and individual equity dynamics, and maintaining relationships with broker/dealer counterparties. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF. Milind Deshpande is a Venture Partner at RA Capital, and President & CEO of Nayan Therapeutics, a RA Capital portfolio company. Anthony has a BS in Molecular and Cellular Biology from University of Arizona and a PhD in Genetics and Molecular Biology from University of North Carolina at Chapel Hill. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Daniel Slesinski is an Associate within the Planetary Health division at RA Capital Management. Prior to RA, Gunes served as a scientist within the PCMM Program at Boston Childrens Hospital and her research focused on biophysical characterization of different amyloid fibrils. She holds a BS in Finance from Elon University and an MBA from Babson College. Prior to joining RA Capital, Jeff worked for over 10 years as an institutional equity sales trader, primarily at KCG Holdings, Inc., where he managed the Boston office. Josh holds a BS in Genetics, Genomics, and Biotechnology with a Minor in Business from Brigham Young University. Jeff holds a BA in Economics and Psychology from Georgetown. Peter Kolchinsky Age : 46 Linked companies : ARS Pharmaceuticals, Inc. - Research Alliance Corp. II - Wave Life Sciences Ltd. - Icosavax, Inc. Summary Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Erin holds a Bachelor of Fine Arts degree from the Massachusetts College of Art & Design. Tweet With huge thanks to RA Capital's Alex Martinez-Forte and Jacqueline Rhuda for extensive data analysis. Ross Chikarmane is an Associate with the TechAtlas division of RA Capital Management. Prior to RA, Kevin was a postdoctoral associate at the Broad Institute of MIT and Harvard and an EMBO fellow. Peymans primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to KPMG, TJ worked within the AP/Office Admin function with the Boston Red Sox. After graduation he got $4 Million from Vertex Pharma co-founder Rich Aldrich and started picking biotech stocks at RA. James was a post-doctoral fellow at Massachusetts Institute of Technology and University of California, Berkeley. Alex Martinez-Forte is an Analyst, Strategic Finance at RA Capital Management. Peter Kolchinsky is a father, scientist, investor, teacher, and author. Dan Marks is a Principal on the Venture Team at RA Capital Management. He was Vice President of Merck business development and licensing where he led BD activities in the US (West Coast), Europe, and Asia Pacific region, as well as President of MRL Ventures where he led equity investing in early-stage therapeutics companies. January 3, 2023 Feb 10th, Ed. Previously, Michael worked closely with the Investment Team, to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Matthew Hammond is a Principal on the Investment Team at RA Capital Management. Cosmass academic research has been published in journals such as Cell, Science, and Nature. Kathryn has a BS in Exercise and Health Science from the University of Massachusetts Boston. Prior to Schrdinger, Cony was President Chief Business Officer at Proteros responsible for all commercial activities. Emory Werner is an Associate with the TechAtlas division of RA Capital Management. From 2016-2017, Scott served as President of Sojournix, Inc., an asset-focused biopharmaceutical company that he co-founded and served as Board member until 2021. His research investigated chromatin structure and transcription factor binding. Emily Greenis a Visual Identity Designer at RA Capital Management. James has over 25 years of industry experience in creating and building biotechnology companies including experience as a co-founder of the lysosomal storage diseases company Vtesse acquired by Sucampo/Malinkrodt, co-founder of the clinical stage neuroendocrine company Tiburio, Board Director of the ocular gene therapy company Nightstar acquired by Biogen, and as founding Chief Scientific Officer of the rheumatology therapy company Synovex/Adheron acquired by Roche. Candice Galvez is an Executive Assistant at RA Capital Management. as a Staff Accountant. Angela has a BA in Pre-Medicine and French Studies from the University of Minnesota. He holds a BS in Biology from the College of William and Mary, where he studied the impact of ecological fragmentation on the prevalence of ticks and their bacterial pathogens. and Ultragenyx Pharmaceuticals. Raj previously worked as a Senior Project Leader at Altus Pharmaceuticals, a spin-off company of Vertex Pharmaceuticals, where he assessed business processes and implemented system solutions across all areas of science. Peter Kolchinsky An excellent example of when knowledge meets power, former Harvard virology doctoral recipient Kolchinsky has put his brainpower to work behind RA Capital Management, with astonishing results in biotech specialization. Gabes primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Sonia has a BA in Chemistry and a PhD in Bioengineering, both from the University of Pennsylvania. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities. Chriss primary responsibility at RA Capital is to cover the biotech and pharma industry. Scott received his Bachelor of Science from the University of Illinois and his Ph.D. from the Massachusetts Institute of Technology. Prior to Indigo, Kathryn was Investment Principal at the Massachusetts Clean Energy Center (MassCEC) where she invested in enterprise and consumer-facing clean energy companies, including software and hardware companies focused on utility and grid resilience, grid edge, next-generation renewables, efficient mobility, industrial efficiency, sustainable buildings, and the water-energy nexus. She earned an MBA with focus in entrepreneurship & strategic management from AB Freeman School of Business at Tulane University and her MD from Tulane School of Medicine. Alyssa previously worked as a Senior Scientist at Eagle Pharmaceuticals. He earned an MS in chemical engineering and his MBA and PhD in engineering systems from MIT. TJ has a BS in Business Administration with a concentration in Accounting from Northeastern University. He received his doctorate in Organic Chemistry from Ohio University, and was a Fellow and Instructor in Department of Medicine, Boston University School of Medicine. Joel is currently a Venture Partner at RA Ventures focusing on new company creation. TJ is a Senior Fund Accountant at RA Capital Management. Brigid was responsible for starting the venture fund and led investments in multiple sectors, including advanced analytics platforms, biomining and bioremediation, novel chemical leaching, long-duration energy storage, traceability of products, carbon removal, and green steel. Elena Forchielli is an Associate within the Planetary Health division of RA Capital Management. Andrew is a Software Developer at RA Capital Management. She also gained administrative and client services experience in roles she held at Life Time Athletic, EF Education First, and at Beth Israel Deaconess Hospital ICU. Monica previously worked as a Licensing Manager at Partners HealthCare Innovation. Prior to RA, she served as Researcher and Collaborator at New Care, a startup focused on improving access to early childcare for lower income families. She worked previously in desktop publishing and as a freelance designer. Prior to his time at Merck, Michael held discovery leadership roles at Immunext and Tolerx. While in these roles, Emily helped Bluebird grow from 300 to 1000 employees. Jacquelines primary responsibility is to partner with the Investment Team to develop quantitative analyses that inform investment decisions and improve core processes throughout the firm. He was previously a marketing manager at Brighton House Associates, assisting with fundraising campaigns for a diverse group of investment managers, including private equity, venture capital, real estate, and hedge funds. Mario is responsible for partnering with several of our portfolio companies as Board Member or Technical Advisor. Zach Scheiner is a Principal on the Investment Team at RA Capital Management. Lucas holds a BA in Criminal Justice and Philosophy from John Jay College of Criminal Justice in NY, a JD, Privacy Concentration, from Northeastern University School of Law, and is admitted to practice law in MA. Ramaswamy, who just turned 30, has bigger aspirations. Shannon's primary responsibilities are to manage the front desk and office facilities. Sarah teaches a course at Harvard Law School on venture capital fund formation. Christys primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. He earned his MS in Bioinformatics from Boston University. Vikram Sheel Kumar is a Venture Partner at RA Capital where he is applying software to develop drugs and new ventures. Previously, Derek covered solid tumor oncology landscapes. Mario held a Project Director position at BARDA working on Universal Flu Vaccine and leading the technical selection and completion of multiyear/multi million vaccine development programs. Sri Mahendra is a Senior Software Engineer at RA Capital Management. Peterconducts due diligence on biotechnology companies at RA Capital, and advises RA's portfolio companies on many aspects of program and pipeline strategy. Michaels primary responsibility at RA Capital is to start and maintain relationships with current and potential investors. Before joining Proteon, Tim was the COO of Trine Pharmaceuticals and he held several management positions with GelTex Pharmaceuticals prior to its acquisition by Genzyme. She works with RAs newcos to develop optimal pitch decks and public messaging, authors articles, and runs the firms internal and external business courses. His doctoral research focused on breast cancer metastasis. Prior to RA, Chris was at Elsevier Business Intelligence, where he served as Writer/Editor and eventually became the Editor in Chief for Biopharmaceuticals and Consumer Products. Michael has more than two decades of experience in immuno-oncology and immunology research in both large pharma and biotech settings. Craig holds a BA in Political Science from Bridgewater State College and a JD from Boston College Law School. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. He holds a Masters degree in Software Engineering from Brandeis University and a BA in Psychology from Providence College. 4. Prior to Baupost, he spent over five years as a Controller at Centerbridge Partners, LP, where he was responsible for accounting and valuation for the credit fund business, as well as the management company (US and Europe) and associated functions. Elena's primary responsibility at RA Capital is to create competitive landscapes of biotechnology and planetary health. Shannon has a BA in Special Education and English from Bridgewater University and a MS in Elementary Education from Boston College. in Biomedical Anthropology from the University of Pennsylvania. Cosmas received his BS in Physics from Massachusetts Institute of Technology and his MD from Rutgers-New Jersey Medical School. Chris has a BS in Neurobiology and Behavior from Cornell University and a MA in Journalism from New York University. While at Acceleron he successfully launched the company's first blockbuster asset - REBLOZYL - and brought in the company's lead drug - Sotatercept - prior to Acceleron's eventual sale to Merck in 2021. Shan Shan holds a PhD in Neuroscience from Harvard University and a BS in Brain and Cognitive Sciences from MIT. Mariagrace has a BS in Sociology from Suffolk University. She holds a BS in Corporate Finance & Accounting and an MBA from Salem State University. Phi previously worked as an Executive Assistant at Relay Therapeutics. Joeys primary responsibility is to manage workflows for investor transaction processing and investor reporting in collaboration with the fund's administrator. Phi Thach is an Executive Assistant at RA Capital Management. Prior to Sage, he had a 14-year tenure at Biogen in various business and commercial roles. Michael holds a B.S. Emily Minkow is a Venture Partner at RA Ventures. Rezs primary responsibility is to lead early-stage private investments in, and oversee the creation of, new companies developing therapeutics and other medical technologies. Brackett has a BS in Biology with a minor in Spanish from Davidson College. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and reasonably well-trained dog. Milind attended the residential Executive Program at The Wharton School of Management. In addition, Cosmas has co-founded companies including Design Pharma (synthetic bio) and a company in stealth focused on RNA based genetic medicines. Nate has a BS in Biological Sciences from University of Vermont. I would love to talk to the 1 out of 7 VCs who thinks non-orphan small molecules for older patients are just as investable post In his role at Catamaran, he helped secure a Series A financing with a syndicate of leading investors, rapidly recruit an experienced cell therapy team, access enabling technologies, build a broad patent estate, and design external communication strategies. Prior to founding The Branta Group LLC in 2003, he was a co-founder and Chief Business Officer of Orchid GeneShield, a subsidiary of Orchid BioSciences (Nasdaq: ORCH), which was formed after he acquired a healthcare informatics company and merged it with Orchids pharmacogenetics business to create innovative personalized consumer healthcare products in partnership with leading healthcare companies. Prior to Biogen, Mike worked at Bain & Company as a consultant specializing in healthcare. But there are only so many vaccine experts. Harveys primary responsibility is to oversee all accounting related activities for the firm. Benjamins primary responsibilities at RA Capital are to coordinate various projects across the Venture Team and oversee their initiation, planning, and execution. Sophie is Chief Medical Officer at Enara Bio, a company focused on novel targets for cancer immune therapy drug discovery. Rez has also held roles at Novartis, a virtual R&D company (BVD), and Xcellsyz Ltd, a UK-based start-up. Prior to his career at the Broad Institute, Robert was an MIT Leaders for Manufacturing Fellow, and a project manager for Fluor Corporation, where he managed large-scale petrochemical design and construction projects. Monicas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. As Head of Vaccines, he is leading the RA vaccine team to support our evidence-based investment strategy. At Corning, he held a number of sales and marketing roles with increasing responsibility; in his last position at Corning, Cony was responsible for marketing at a new business unit focused on high-throughput screening and molecular biology products. Megans primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Ana holds an MPH in Epidemiology and Biostatistics from Boston University School of Public Health and a BA in Neuroscience from Boston University. Christinas primary responsibility is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Peter Kolchinsky Number of IPOs: 18. Jesse earned his Ph.D. in Biological Chemistry from MIT and was a Harvard Origins Research Fellow. However he's a bit older than others, like Raquel Leviss, who is only 28 . Prior to joining Aberdeen, Eric worked as a Compliance Examiner at the US Securities and Exchange Commission. Jake works on both public and private investments and serves as a Board Director for Xenikos, B.V, Tyra Biosciences, AavantiBio, and DiCE Molecules. Previously he served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. Prior to joining Achillion, Milind was Group Leader at Bristol-Myers Squibb for all early stage discovery programs in infectious diseases and neuroscience. Natalie holds a BA in Psychology from William Paterson University and a MA in Psychology from Seton Hall University. As political refugees, the family was placed in Milwaukee, then Pittsburgh. Prior to Point32Health, Michael served as CMO of Harvard Pilgrim Health Care, the Corporate Medical Director at Humana and also served as Vice President of Network and Consumer Solutions for UnitedHealth Groups subsidiary Ingenix (now part of Optum). Most recently, she was as an Entrepreneur-in-Residence at RA Ventures and was a Scientific Co-Founder and Associate Director of Corporate Development at Athenen Therapeutics (merged into Eliem Therapeutics; ELYM). TipRanks & Hedge Funds: TipRanks measures the performance of Peter Kolchinsky and other hedge fund managers based on information submitted to the SEC. Walter Dauksher is a Junior Associate within the Planetary Health division of RA Capital Management. After joining RA Ventures as Chief Development Officer, Ed built the development team, oversaw development of six compounds from discovery-stage through to clinical-stage, and led the formation of several new companies, including Lusaris Therapeutics. PETER KOLCHINSKY, PhD Managing Partner RAJEEV SHAH Managing Partner ANDREW LEVIN, MD/PhD Partner and Managing Director JOSH RESNICK, MD Senior Managing Director PETER BALOGH Analyst GUNES BOZKURT, PhD Analyst TESS CAMERON Principal NATE DAVIS Analyst DEREK DiROCCO, PhD Partner CRISTINA GHENOIU, PhD Principal MICHAEL GILLESPIE, MD Analyst In this position, he played a critical role in building Mercks oncology pipeline into one of the most robust in cancer immunotherapy, focusing on a modality-agnostic strategy with a broad biology of targets and Keytruda combination strategies. Jaime is an Executive Assistant at RA Ventures (RAVen). Emory has a BS from Vassar College and an MD from the Harvard-MIT Health, Science, Technology Program at Harvard Medical School. Previously, Emily spent over seven years at Celgene Corporation in positions of increasing responsibility in business development, marketing, operations, and as Principal to the Chairman and CEO. Currently, he serves as Chief Technology Officer at Danaher, with a focus on new genomic medicines. Prior to RA, Rob spent 21 years at the Broad Institute of MIT and Harvard, most recently as the Senior Director of Technology Development and a Principal Investigator. Prithviraj has a BS from Duke University and an MBA from Kellogg School of Management, Northwestern University. Mariagrace Houllahan is an Executive Assistant at RA Capital Management. Matts primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Ed Monaghan is an EIR at RA Capital. He is a member of the Advisory Boards of the Applied Biotechnology Laboratory at the Francis Crick Institute, the Center for Surgery,Innovation & Bioengineering at the Massachusetts General Hospital/Harvard MedicalSchool; the Chemical& Biomolecular Engineering Department of the University of Illinois and the Biomedical Engineering Departmentof Rutgers University. Hearing the stories of how patients couldn't afford the . He holds additional board appointments with several well-respected nonprofit organizations, including the Institute for Clinical and Economic Review (ICER), the Personalized Medicine Coalition, the Harvard Business School Healthcare Initiative, NEHI (Network for Excellence in Health Innovation), and the Massachusetts Rare Disease Advisory Council. Ernesto Gonzalez is a Business Systems Manager at RA Capital. Meredith is a Senior Research Assistant at RA Capital Management. Peter Kolchinsky @PeterKolchinsky 2h So competition among vaccine innovators required collaboration to expand production and rewards were high enough to hire all capable people in the world to work on this. Ross has a BS in Biochemistry from University of Oregon and a PhD in Pharmacology & Molecular Sciences from Johns Hopkins University. He was also a Board Member of the Fannie & John Hertz Foundation and served as a judge for the Lemelson-MIT StudentPrize for Inventorship. Michael has also previously held the position of Vice President and General Manager at Thomson Medstat (now part of IBM Watson Health), as well as held management roles at Immusol, a San Diego-based biotechnology company, HealthAllies, an organization created to provide discretionary medical benefits to the cash-pay market, and Da Vita, a national provider of dialysis services. RA Capital and CEO of Arcuate Therapeutics. Megan Lipcsey is an Associate with the TechAtlas division of RA Capital Management. Most recently, Brendan served as Tax Director at PwC Asset & Wealth Management. Robert also led the Sequencing Operations and Technology Development groups at the Broad for over 12 years, implementing industrial process control methods, developing multiple generations of high-throughput DNA sequencing technologies, and establishing an agile learning culture in the organization. Garrett received a BS with honors from the California Institute of Technology while publishing his first paper with Dr. Paul H. Patterson, holds a PhD in Immunology from Stanford University, where he studied hematopoietic stem and progenitor cells with Dr. Irving L. Weissman, and completed his post-doctoral training at Childrens Hospital Boston/Harvard Medical School studying ES/iPSC specification to the hematopoietic fate with Dr. George Q. Daley.
Beanie Babies List With Pictures,
Lidl Raisin Custard Swirl,
Stephen Jones Daughter Wedding,
Thursley Common Boardwalk Map,
Atom Rpg Best Weapons,
Articles P